ACOR News and Press, Acorda Therapeutics Inc. From 04/15/22

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...

Acorda Therapeutics, Inc. (ACOR) Q4 2021 Earnings Conference Call March 9, 2022 16:30 ET Company Participants Tierney Saccavino - Executive Vice President, Corporate Communications Ron Cohen - Chief Executive Officer Mike Gesser - Chief Financial Officer Conference Call Participants Muzamil S...

Acorda Therapeutics (NASDAQ:ACOR) is up 2% in after-hours trading following the biotech's Q4 2021 and full-year earnings. The company's net loss narrowed 75% in the quarter to $20.6M (-$1.73 per share, basic and diluted) compared to the prior-year period. Revenue of ~$37M was a ~3% ...

Acorda Therapeutics press release (NASDAQ:ACOR): Q4 Non-GAAP EPS of -$0.67. Revenue of $36.07M (-5.5% Y/Y) beats by $5.06M. For further details see: Acorda Therapeutics Non-GAAP EPS of -$0.67, revenue of $36.07M beats by $5.06M

AMPYRA ® (dalfampridine) Extended Release Tablets, 10 mg 2021 net revenue of $84.6 million AMPYRA Q4 2021 net revenue of $22.5 million INBRIJA ® (levodopa inhalation powder) 2021 net revenue of $29.6 million; 22% increase over 2020 INBRIJA Q4 2021 net rev...

Acorda Therapeutics (NASDAQ:ACOR) is scheduled to announce Q4 earnings results on Wednesday, March 9th, after market close. The consensus EPS Estimate is -$1.11 (compared to -$2.50 in the year ago quarter) and the consensus Revenue Estimate is $31.01M (-18.7% Y/Y). Over the last 2 years, ACOR...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...

Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a webcast/conference call in conjunction with its fourth quarter and year end 2021 update and financial results on Wednesday, March 9 at 4:30 p.m. ET. To participate in the Webcast, please use the following pre-registration link: ...

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Ron Cohen, MD, President and CEO, will present at the H.C. Wainwright BIOCONNECT Virtual Conference, taking place from January 10 – 13, 2022. H.C. Wainwright BIOCONNECT Conference Date: January 10 – 13...